Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

Conditions

Advanced Solid Tumors Metastatic Solid Tumors Non-small Cell Lung Cancer (NSCLC)NSCLC Colorectal Cancer (CRC)CRC

Interventions / Drugs

Daraxonrasib Elironrasib Zoldonrasib Ivonescimab Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)cetuximab (Cohort C2 Only)Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)Daraxonrasib (Cohort B1 only)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment370 participants

Primary Completion—

Lead SponsorRevolution Medicines, Inc.

Data Retrieved2026-04-11 04:26:28.070724+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.